Early trial tests new vaccine combo to train immune system against aggressive breast cancer
NCT ID NCT02826434
Summary
This early-stage study is testing a new vaccine (PVX-410) alone and combined with an immunotherapy drug (durvalumab) for women who have already finished standard treatment for stage II or III triple-negative breast cancer. The main goals are to check if the treatments are safe and to see if they can trigger the patient's own immune system to recognize and attack any remaining cancer cells. It is a small, initial study to gather safety and early response data.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33607, United States
-
Massachusetts general Hospital
Boston, Massachusetts, 02114, United States
-
New York University School of Medicine
New York, New York, 10016, United States
Conditions
Explore the condition pages connected to this study.